KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Accounts Payables (2016 - 2026)

Abbott Laboratories' Accounts Payables history spans 18 years, with the latest figure at $4.7 billion for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 11.03% to $4.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $4.7 billion, a 11.03% increase, with the full-year FY2025 number at $4.2 billion, up 1.07% from a year prior.
  • Accounts Payables hit $4.7 billion in Q1 2026 for Abbott Laboratories, up from $4.2 billion in the prior quarter.
  • Over the last five years, Accounts Payables for ABT hit a ceiling of $4.8 billion in Q1 2022 and a floor of $4.0 billion in Q3 2023.
  • Historically, Accounts Payables has averaged $4.3 billion across 5 years, with a median of $4.2 billion in 2023.
  • Biggest five-year swings in Accounts Payables: increased 16.99% in 2022 and later fell 12.4% in 2023.
  • Tracing ABT's Accounts Payables over 5 years: stood at $4.6 billion in 2022, then dropped by 6.77% to $4.3 billion in 2023, then fell by 2.33% to $4.2 billion in 2024, then grew by 1.07% to $4.2 billion in 2025, then rose by 10.35% to $4.7 billion in 2026.
  • Business Quant data shows Accounts Payables for ABT at $4.7 billion in Q1 2026, $4.2 billion in Q4 2025, and $4.1 billion in Q3 2025.